These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 10090596)
1. Chemotherapy of Chagas' disease: the how and the why. Urbina JA J Mol Med (Berl); 1999 Mar; 77(3):332-8. PubMed ID: 10090596 [TBL] [Abstract][Full Text] [Related]
2. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Urbina JA; Payares G; Contreras LM; Liendo A; Sanoja C; Molina J; Piras M; Piras R; Perez N; Wincker P; Loebenberg D Antimicrob Agents Chemother; 1998 Jul; 42(7):1771-7. PubMed ID: 9661019 [TBL] [Abstract][Full Text] [Related]
4. Cure of short- and long-term experimental Chagas' disease using D0870. Urbina JA; Payares G; Molina J; Sanoja C; Liendo A; Lazardi K; Piras MM; Piras R; Perez N; Wincker P; Ryley JF Science; 1996 Aug; 273(5277):969-71. PubMed ID: 8688084 [TBL] [Abstract][Full Text] [Related]
5. The dog as model for chemotherapy of the Chagas' disease. Guedes PM; Veloso VM; Tafuri WL; Galvão LM; Carneiro CM; Lana Md; Chiari E; Ataide Soares K; Bahia MT Acta Trop; 2002 Oct; 84(1):9-17. PubMed ID: 12387906 [TBL] [Abstract][Full Text] [Related]
6. Specific treatment of Chagas disease: current status and new developments. Urbina JA Curr Opin Infect Dis; 2001 Dec; 14(6):733-41. PubMed ID: 11964893 [TBL] [Abstract][Full Text] [Related]
7. Ergosterol biosynthesis and drug development for Chagas disease. Urbina JA Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():311-8. PubMed ID: 19753490 [TBL] [Abstract][Full Text] [Related]
8. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Urbina JA; Payares G; Sanoja C; Molina J; Lira R; Brener Z; Romanha AJ Int J Antimicrob Agents; 2003 Jan; 21(1):39-48. PubMed ID: 12507836 [TBL] [Abstract][Full Text] [Related]
9. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Guedes PM; Urbina JA; de Lana M; Afonso LC; Veloso VM; Tafuri WL; Machado-Coelho GL; Chiari E; Bahia MT Antimicrob Agents Chemother; 2004 Nov; 48(11):4286-92. PubMed ID: 15504854 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138 [TBL] [Abstract][Full Text] [Related]
12. Match-making for posaconazole through systems thinking. Fügi MA; Kaiser M; Tanner M; Schneiter R; Mäser P; Guan XL Trends Parasitol; 2015 Feb; 31(2):46-51. PubMed ID: 25486978 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of Chagas disease. Urbina JA Curr Pharm Des; 2002; 8(4):287-95. PubMed ID: 11860367 [TBL] [Abstract][Full Text] [Related]
14. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives. Urbina JA J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065 [TBL] [Abstract][Full Text] [Related]
15. Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infection. Bisio MMC; Jurado Medina LS; García-Bournissen F; Gulin JEN Parasitol Res; 2024 Jun; 123(6):248. PubMed ID: 38904688 [TBL] [Abstract][Full Text] [Related]
16. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. Molina J; Brener Z; Romanha AJ; Urbina JA J Antimicrob Chemother; 2000 Jul; 46(1):137-40. PubMed ID: 10882704 [TBL] [Abstract][Full Text] [Related]
17. Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease. Vilar-Pereira G; Resende Pereira I; de Souza Ruivo LA; Cruz Moreira O; da Silva AA; Britto C; Lannes-Vieira J Antimicrob Agents Chemother; 2016 Jul; 60(7):4297-309. PubMed ID: 27161638 [TBL] [Abstract][Full Text] [Related]
18. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376 [TBL] [Abstract][Full Text] [Related]
19. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Diniz Lde F; Caldas IS; Guedes PM; Crepalde G; de Lana M; Carneiro CM; Talvani A; Urbina JA; Bahia MT Antimicrob Agents Chemother; 2010 Jul; 54(7):2979-86. PubMed ID: 20404124 [TBL] [Abstract][Full Text] [Related]
20. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease. Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]